Original Article

You have full text access to this OnlineOpen article

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma†

  1. Revathi Suppiah MD1,
  2. Philip E. Shaheen MD1,
  3. Paul Elson ScD1,
  4. Seema A. Misbah MD1,
  5. Laura Wood RN1,
  6. Robert J. Motzer MD2,
  7. Slyvie Negrier MD, PhD3,
  8. Steven W. Andresen DO1,
  9. Ronald M. Bukowski MD1,‡,*

Article first published online: 18 SEP 2006

DOI: 10.1002/cncr.22237

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1793–1800, 15 October 2006

Additional Information

How to Cite

Suppiah, R., Shaheen, P. E., Elson, P., Misbah, S. A., Wood, L., Motzer, R. J., Negrier, S., Andresen, S. W. and Bukowski, R. M. (2006), Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer, 107: 1793–1800. doi: 10.1002/cncr.22237

Author Information

  1. 1

    Department of Hematology and Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio

  2. 2

    Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  3. 3

    Division of Oncology, Centre Leon Berard, Lyons Cedex, France

  1. ‡

    Fax: (216) 444-9464

*Cleveland Clinic Foundation, Taussig Cancer Center, 9500 Euclid Avenue, R35, Cleveland, OH 44195

  1. †

    Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13–17, 2005.

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 18 SEP 2006
  3. Manuscript Accepted: 9 AUG 2006
  4. Manuscript Revised: 7 AUG 2006
  5. Manuscript Received: 26 MAY 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (129K)

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106–130.
    Direct Link:
  • 2
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688–696.
  • 3
    Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987; 14(2 suppl 2 ): 36–42.
  • 4
    Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993; 20: 303–321.
  • 5
    Motzer R, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Presented at the American Society of Clinical Oncology; May 13–17, 2005; Orlando, FL.
  • 6
    Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of Soranfenib (BAY 43-9006)-an oral multikinase inhibitor-in patients with advanced RCC. Presented at the American Society of Clinical Oncology; May 13–17, 2005; Orlando, FL.
  • 7
    Van Brussel JP, Mickisch GH. Prognostic factors in renal cell and bladder cancer. BJU Int. 1999; 83: 902–908; quiz 908–909.
    Direct Link:
  • 8
    Ficarra V, Righetti R, Pilloni S, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol. 2002; 41: 190–198.
  • 9
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27: 612–624.
  • 10
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530–2540.
  • 11
    Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289–296.
  • 12
    Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med. 1964; 114: 497–500.
  • 13
    Blay JY, Favrot M, Rossi JF, et al. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood. 1993; 82: 2261–2262.
  • 14
    Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000; 86: 203–207.
    Direct Link:
  • 15
    Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol. 2002; 13: 1460–1468.
  • 16
    O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol. 2002; 168(4 pt 1): 1378–1380.
  • 17
    Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol. 2004; 11: 364–367.
    Direct Link:
  • 18
    Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology. 2004; 63: 447–450.
  • 19
    Kies MS, Posch JJJr., Giolma JP, Rubin RN. Hemostatic function in cancer patients. Cancer. 1980; 46: 831–837.
    Direct Link:
  • 20
    Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol. 1987; 88: 596–602.
  • 21
    Miller SP, Sanchez-Avalos J, Stefanski T, Zuckerman L. Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer. 1967; 20: 1452–1465.
    Direct Link:
  • 22
    Burstein SA, Harker LA. Control of platelet production. Clin Haematol. 1983; 12: 3–22.
  • 23
    Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood. 1990; 76: 50–56.
  • 24
    Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood. 1990; 75: 1602–1605.
  • 25
    Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol. 1991; 79: 286–290.
    Direct Link:
  • 26
    Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 3317–3322.
  • 27
    Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J Urol. 1992; 148: 1778–1781; discussion 1781–1782.
  • 28
    Dosquet C, Schaetz A, Faucher C, et al. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer. 1994; 30A: 162–167.
  • 29
    Walther MM, Johnson B, Culley D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998; 159: 718–722.
  • 30
    Kaushansky K. Regulation of megakaryopoiesis. 3rd ed. Philadelphia: Williams & Wilkins; 2003.
  • 31
    Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol. 1997; 25: 565–572.
  • 32
    Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood. 1998; 92: 2189–2191.
  • 33
    Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001; 98: 2720–2725.
  • 34
    Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981; 95: 636–641.
  • 35
    Smith MSH, Rothman V. Thrombospondin (TSP) levels in patients with malignancy. Proc Am Soc Clin Oncol. 1990: 6.
  • 36
    Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res. 1987; 47: 4130–4133.
  • 37
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182–1186.
  • 38
    Mohle RGD, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci. 1997: 663–668.
  • 39
    Folkman J. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997.
  • 40
    O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet. 1999; 353: 1494–1495.
  • 41
    Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol. 1996; 7: 843–848.
  • 42
    Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992; 11: 325–351.
  • 43
    Jones CL, Witte DP, Feller MJ, Fugman DA, Dorn GW2nd, Lieberman MA. Response of a human megakaryocytic cell line to thrombin: increase in intracellular free calcium and mitogen release. Biochim Biophys Acta. 1992; 1136: 272–282.
  • 44
    Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003; 162: 1083–1093.
  • 45
    Teraoka H, Sawada T, Nishihara T, et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer. 2001; 85: 612–617.
  • 46
    Vinals F, Pouyssegur J. Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol. 2001; 21: 7218–7230.
View Full Article (HTML) Get PDF (129K)